TAK-875(Fasiglifam),GPR40Agonist
如果您對該產品感興趣的話,可以
產品名稱: TAK-875(Fasiglifam),GPR40Agonist
產品型號: M60220-2s
產品展商: 其它品牌
產品文檔: 無相關文檔
簡單介紹
TAK-875(Fasiglifam),GPR40Agonist
TAK-875(Fasiglifam),GPR40Agonist
的詳細介紹
Product Information
Molecular Weight: |
533.63 |
Formula: |
C29H32O7S.1/2H2O
|
Purity: |
≥98% |
CAS#: |
1374598-80-7 |
Solubility: |
DMSO up to 100 mM |
Chemical Name: |
(S)-2-(6-((2',6'-dimethyl-4'-(3-(methylsulfonyl)propoxy)-[1,1'-biphenyl]-3-yl)methoxy)-2,3-dihydrobenzofuran-3-yl)acetic acid |
Storage: |
Powder: 4oC 1 year.
DMSO: 4oC 3 month;
-20oC 1 year. |
Biological Activity:
TAK-875
(Fasiglifam) is the potent, selective
and orally bioavailable partial GPR40 agonist with an EC50 ~14 nM. ?It has binding affinity to the human GPR40
receptor with Ki of 38 nM and the rat GPR40 receptor with Ki of 140 nM. TAK-875
has no agonist potency to other members of the FFA receptor family with EC50
>10 μM. The 2.3 ? resolution co-complex structure of hGPR40-TAK-875 reveals
a unique binding mode of TAK-875 and suggests that entry to the non-canonical
binding pocket most probably occurs via the lipid bilayer. Consistent with the
activation of the Gqα-mediated signaling pathway, TAK-875 augments
glucose-dependent insulin secretion in pancreatic β cells. Prolonged
stimulation of GPR40/FFA1 by TAK-875 does not cause pancreatic β Cell
dysfunction or induction of apoptosis. Termination phase III development of
TAK-875 (Fasiglifam) for the potential treatment of type-2 diabetes mellitus was
announced in 2013 due to concerns about liver safety.
How to Use:
- In vitro:?
TAK-875 was used at 1 μM final concentration in various in vitro assays.
- In vivo: TAK-875 was dosed to female
Wistar fatty rats subjected to oral glucose tolerance test via oral gavage at 3
mg/kg one hour before an oral glucose challenge. Formulation is 0.5% CMC/0.25%
Tween 80 in water. In type 2 diabetic N-STZ-1.5 rats, administration of TAK-875
(1-10 mg/kg PO) shows a clear improvement in glucose tolerance and augments insulin
secretion. TAK-875 (10 mg/kg, PO) significantly augments plasma insulin levels
and reduces fasting hyperglycemia in male Zucker diabetic fatty rats.?
Reference:?
- 1.?????
Negoro
N, et al. Discovery of TAK-875: A Potent, Selective, and Orally Bioavailable
GPR40 Agonist. (2010) ACS Med Chem Lett. 1(6):290-4.
- 2.?????
Tsujihata
Y, et al. TAK-875, an orally available G protein-coupled receptor 40/free fatty
acid receptor 1 agonist, enhances glucose-dependent insulin secretion and
improves both postprandial and fasting hyperglycemia in type 2 diabetic rats. (2011) J Pharmacol Exp Ther. 339(1):228-37.
- 3.?????
Srivastava A, et al. High-resolution structure
of the human GPR40 receptor bound to allosteric agonist TAK-875. (2014) Nature.
513(7516):124-7.?
? ??
? ??
Products are for research use only. Not for human use.
?